PROTEUS May Mean New SOC for Some Prostate Cancers - PubMed
2 hours ago
- #prostate-cancer
- #oncology-treatment
- #clinical-trial
- PROTEUS trial shows 6-month apalutamide plus ADT before/after surgery improves outcomes in localized high-risk prostate cancer vs. ADT alone.
- At 5 years, 78.2% on apalutamide+ADT were metastasis-free vs. 73.5% on ADT only, reducing metastasis and death risk.
- Findings may establish apalutamide+ADT as a new standard of care for this patient group.